8-K: NKGen Biotech Secures $5 Million Convertible Loan to Refinance Debt

NKGen Biotech entered into a convertible loan agreement for up to $5 million with AlpineBrook Capital to refinance existing debt and issued warrants and shares as consideration.

Summary

• NKGen Biotech, Inc. has entered into a convertible loan agreement with AlpineBrook Capital GP I Limited for a term loan of up to $5 million.
• A $1 million advance was provided prior to the closing, with the remaining balance to be drawn according to an agreed-upon schedule.
• The loan bears interest at 12% per annum.
• As consideration, NKGen Biotech issued 333,333 shares of common stock and a warrant to purchase 333,333 shares of common stock to AlpineBrook Capital.
• Future drawdowns will result in additional consideration shares and warrants equal to one-third of the drawdown amount.
• The warrant has a five-year term and an exercise price of $0.25 per share, subject to adjustments.
• The loan proceeds will be used to repay the company's outstanding senior secured debt with East West Bank.
• The lender has the right to convert the outstanding principal and unpaid interest into common stock at a conversion price of $0.25 per share, subject to adjustments and limitations.
• The note matures one year from when the borrower receives $5,000,000, one year from when the lender terminates the loan, when the debt is accelerated, or an earlier agreed upon date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The loan provides needed capital, but also introduces potential dilution and increased debt obligations. The high interest rate is a concern.

Positives

• The loan provides NKGen Biotech with capital to refinance existing debt, potentially improving its financial structure.
• The convertible feature offers the lender potential upside through equity participation.
• The initial advance of $1 million provides immediate financial relief.
• The loan allows NKGen Operating Biotech, Inc. to be jointly and severally liable for all obligations.

Negatives

• The loan increases NKGen Biotech's debt obligations.
• The conversion of the loan into equity could dilute existing shareholders' ownership.
• The lender has the right to terminate the utilization of this Term Loan, whether in whole or in part and whether by whatsoever reasons, by giving notice to the Loan Parties.
• The Beneficial Ownership Limitation is 4.99% of the number of shares of the Common Stock outstanding at the time of the respective calculation hereunder.

Risks

• Dilution of existing shareholders if the lender converts the loan into common stock.
• The company's ability to meet its debt obligations, including interest payments.
• Potential for adjustments to the exercise price and conversion price based on future stock issuances or corporate actions.
• The lender has the right to terminate the utilization of this Term Loan, whether in whole or in part and whether by whatsoever reasons, by giving notice to the Loan Parties.
• The Beneficial Ownership Limitation is 4.99% of the number of shares of the Common Stock outstanding at the time of the respective calculation hereunder.

Future Outlook

The company plans to use the loan proceeds to refinance existing debt, which could improve its financial stability. Future drawdowns from the term loan will be based on a schedule to be agreed upon by the parties.

Industry Context

Biotech companies often utilize convertible loans as a means of financing research and development or refinancing existing debt. The terms of these loans, including interest rates, conversion prices, and warrant issuances, can vary significantly based on the company's financial health and market conditions.

Comparison to Industry Standards

• Comparable companies in the biotech industry, such as BioNTech and Moderna, have also utilized convertible notes to raise capital.
• The interest rate of 12% is relatively high, suggesting that NKGen Biotech may have had limited access to other financing options or that the lender perceived a higher level of risk.
• The conversion price of $0.25 per share will be compared to the market price of NKGen Biotech's stock at the time of conversion to determine the actual dilution impact on existing shareholders.
• The warrant coverage of 333,333 shares is a standard incentive for lenders in convertible loan agreements.

Stakeholder Impact

• Shareholders may experience dilution if the loan is converted into equity.
• Employees may benefit from the company's improved financial stability.
• Creditors may be impacted by the refinancing of existing debt.
• Customers and suppliers may see little immediate impact, but the long-term stability of the company could be affected.

Next Steps

• NKGen Biotech will use the loan proceeds to repay its outstanding senior secured debt with East West Bank.
• The company will need to manage its debt obligations and potential dilution from the convertible feature.
• The remaining balance of the term loan will be drawn according to a schedule to be agreed upon by the parties.
• The company may need to seek shareholder approval for the issuance of conversion shares and warrant shares if required by Nasdaq rules.

Key Dates